Hereditary Testing Market

Market Overview The Global Hereditary Testing Market is expected to expand significantly, growing from USD 6.73 Billion in 2025 to USD 10.61 Billion by 2031, demonstrating a Compound Annual Growth Rate (CAGR) of 7.88%. Hereditary testing involves the laboratory examination of human DNA, chromosomes, or proteins to identify genetic variations linked to inherited conditions or disease predispositions. Key growth catalysts include the increasing prevalence of chronic diseases with genetic components and the declining expenses associated with genomic sequencing. These elements facilitate the integration of preventative genetic screening into standard healthcare practices, underscored by projections of 2,041,910 new cancer cases in the United States in 2025, according to the American Cancer Society, emphasizing the urgent need for accessible early risk identification.However, a major obstacle to this market's growth is the absence of standardized reimbursement policies and consistent insurance coverage for genetic services. Varied payment structures across regions lead to financial impediments, limiting patient access to crucial hereditary tests and hindering wider adoption by medical facilities. Market Driver The Global Hereditary Testing Market is significantly propelled by rapid advancements in Next-Generation Sequencing (NGS) technologies, which substantially improve test throughput and accessibility. Ongoing developments in genomic sequencing platforms allow laboratories to process large quantities of samples more quickly and affordably, thereby fostering the widespread integration of carrier screening and prenatal testing. This enhanced scalability is demonstrated by key industry players, with Natera processing approximately 3,064,600 tests in 2024, as reported in February 2025, reflecting significant volume growth driven by technological capacity and enabling healthcare providers to incorporate extensive genetic insights into routine patient care, moving from narrow panels to broader exome and genome analyses.Furthermore, increasing demand for personalized medicine and precision therapeutics fuels market expansion, especially in oncology where genetic profiling is crucial for treatment selection. Clinicians are increasingly utilizing hereditary and somatic testing to pinpoint specific mutations that guide targeted therapies, ensuring treatments are customized to individual genomic profiles. This transition to biomarker-driven care is evident in the rising use of precision oncology diagnostics, with Guardant Health reporting approximately 206,700 oncology clinical tests in 2024, as of February 2025, emphasizing the vital role of genetic diagnostics in cancer management. Additionally, the commercial strength of these services is robust across the sector, with Myriad Genetics reporting third-quarter revenue of $205.7 million in 2025, highlighting sustained financial investment and value creation within the hereditary testing field. Market Challenge A significant constraint on the Global Hereditary Testing Market stems from the absence of standardized reimbursement policies and consistent insurance coverage. The considerable variation in payment models among different regions and insurance providers introduces substantial financial unpredictability for laboratories and medical facilities. This inconsistency compels healthcare institutions to restrict the implementation of genetic screening programs, as they cannot rely on adequate reimbursement for the expenses of these advanced diagnostic services. As a result, patients often face prohibitive out-of-pocket costs or complicated administrative procedures, effectively impeding their access to crucial testing.These financial and administrative obstacles directly contribute to a reduction in the volume of hereditary tests conducted. Data from the American Medical Association in 2024 indicates that 94% of physicians reported delays in necessary care due to prior authorization protocols. This high level of friction in the reimbursement system discourages healthcare providers from ordering hereditary tests for preventative measures, largely confining their use to high-risk diagnostic situations. Sustained market growth and widespread adoption will remain elusive as long as coverage remains fragmented and approval processes continue to be burdensome. Market Trends The integration of Artificial Intelligence (AI) into variant interpretation is profoundly transforming laboratory workflows by addressing the data analysis bottleneck inherent in high-throughput sequencing. As the sheer volume of identified genetic variants exceeds human curation capabilities, laboratories are increasingly deploying machine learning algorithms to automate pathogenicity assessments and prioritize clinically significant findings. This implementation not only speeds up test turnaround times but also sustains high diagnostic accuracy, which is essential for scaling precision medicine. A report from SeqOne in December 2025, 'AI in Clinical Genomics,' noted that their AI-driven analysis solution accurately identified 96% of diagnostic variants within streamlined shortlists, underscoring the substantial efficiency gains and validation of automated interpretation tools in clinical settings.Concurrently, the market is expanding its focus beyond traditional cancer applications to encompass non-oncology hereditary disease applications, thereby broadening the utility of genetic testing. Clinicians are progressively incorporating genomic profiling into fields such as cardiology and pharmacogenomics to enable earlier interventions and optimize medication choices for various chronic conditions. This expansion of clinical scope is driving segment growth as healthcare systems increasingly acknowledge the benefits of preventative screening for a diverse range of cardiovascular and metabolic disorders. Myriad Genetics' 'Fourth Quarter and Full-Year 2024 Financial Results,' released in February 2025, reported a 14% increase in pharmacogenomics testing revenue for the quarter, illustrating the strong commercial momentum of hereditary diagnostics across broader medical specialties. Key Market Players * Myriad Genetics, Inc. * Illumina, Inc. * Natera, Inc. * Laboratory Corporation of America Holdings * F. Hoffmann-La Roche Ltd. * Quest Diagnostics Incorporated * COOPERSURGICAL, INC. * Agilent Technologies, Inc. * Thermo Fisher Scientific, Inc. * SOPHiA GENETICS SA Report Scope In this report, the Global Hereditary Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below: # Hereditary Testing Market, By Disease Type * Hereditary Cancer Testing * Hereditary Non-cancer Testing # Hereditary Testing Market, By Technology * Cytogenetic * Biochemical * Molecular Testing # Hereditary Testing Market, By Region * North America United States Canada Mexico * Europe France United Kingdom Italy Germany Spain * Asia Pacific China India Japan Australia South Korea * South America Brazil Argentina Colombia * Middle East & Africa South Africa Saudi Arabia UAE Competitive Landscape Company Profiles: Detailed analysis of the major companies present in the Global Hereditary Testing Market. Available Customizations: Global Hereditary Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: Company Information * Detailed analysis and profiling of additional market players (up to five).